Sleep apnoea affects many older Australians — but managing it isn’t as difficult or expensive as you might think.

ResMed ( ASX: RMD) shares opened 8% higher as the market opened on Friday after the company reported a better-than-expected ...

ResMed has tracked more than 660,000 patients taking GLP-1 drugs like Wegovy and Zepbound. Patients prescribed a weight-loss drug are 10.5% more likely to start using a CPAP to treat their sleep ...

Our forecast five-year revenue and EBIT compound annual growth rates are 8% and 10%, respectively, broadly consistent with ResMed’s five ... of GLP-1 drugs for weight loss, underlying EBIT ...

A stellar first quarter has underscored ResMed's share price bounce-back from last year's obesity drug panic, and perhaps put ...

A moderate amount of weight loss of 5% to 10% can have a major impact on your health. That’s 9 to 18 pounds (4 to 8 kg) if you weigh 180 pounds (82 kg), and 13 to 25 pounds (6 to 11 kg ...

ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep ...

Broking analysts reckon the impact of fat-busting drugs such as Ozempic on Resmed's share price has been overdone.

The chief executive of sleep devices company Resmed, Mick Farrell, speaks to The Business, dismissing investor fears that a new generation of weight loss drugs like Ozempic threaten demand for ...

Nov. 4, 2024 — Scientists have long suspected the keto diet might be able to calm an overactive immune system and help some people with diseases like multiple sclerosis. Now, they have reason to ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

ResMed stock broke out early Friday after the CPAP maker broadly beat third-quarter projections, shrugging off weight-loss drug worries.